3541. [Seronegative spondyloarthritis].3543. [Significance of the antibody-dependent cellular cytotoxicity (ADCC) test].3544. [Benzbromarone in the treatment of gout].3545. [The immunomodulating effect of levamisole in animal experiments].3546. [Changes in the locomotor system in renal disease].3547. [Significance of HL-A antigens in rheumatic diseases].3548. [Effect of adrenal steroids on the function of cells and the proliferation of viruses].3549. [Role of immunological complexes in rheumatoid arthritis].3550. Immune complexes and induced release of lysosomal enzymes from mononuclear phagocytes in the pathogenesis of rheumatoid arthritis.3551. The properdin pathway: mechanisms of complement activation and analogies to the classical pathway.3552. Altered local metabolism of complement components in rheumatoid arthritis.3554. [Incidence and pathomechanism of thrombocytosis in rheumatoid arthritis].3555. [Transfer factor in the treatment of rheumatoid arthritis in children].3556. [Pathomechanism of amyloidosis development in the light of studies on transfer amyloidosis].3557. Critical evaluation of B and T cell markers in man.3558. [Diagnosis and treatment of cervical spondylosis].3559. Immunosuppressive therapy of immunoinflammatory diseases.3560. [Clinical use of non-steroid anti-inflammatory agents]. |